Cem Yalcinkaya博士は、アナドル医療センターの准教授であり、婦人科腫瘍専門医です。妊孕性温存手術および婦人科がんに対するロボット手術を専門としています。Yalcinkaya博士は、ダヴィンチ・システムにおけるロボット手術の認定資格を保持しています。2019年には、欧州婦人科腫瘍学会（ESGO）の試験に合格しました。
Solak医師は、Hisar Hospital Intercontinentalにて、乳がん、精巣がん、消化器がんなどの複雑ながんの治療を専門としています。
アレムダル医師は、トルコ有数の医療機関であるアクデニズ大学で広範なトレーニングを受けた医療腫瘍学の専門家です。
Zhang Jinshan, male, China’s First M.D. in the Radiation Medicine, CCI (Chinese College of Interventionalists) Master Interventionalist, Director of the Department of Former Radiological Diagnosis at Chinese PLA General Hospital(No.3 in China) Ph.D. of Medicine, Nagasaki University, Japan.
1980–1985: Completed doctoral studies at Nagasaki University, Japan
1968–present: Department of Radiology, Chinese PLA General Hospital
1988: Third Prize of the Military Science and Technology Progress Award
1989–present: Member of Radiological Society of North America(RSNA)
1990–2009: Standing Committee Member of the Radiology and Therapeutic Radiology Committee of the PLA
1991: Second Prize of the Military Science and Technology Progress Award
1992–2008: Group Leader of the Group of Intervention of Chinese Journal of Radiology
1992–2015: Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology
1993: Granted the Lifetime Special Government Allowance of the State Council
1993–2012: Deputy Chief Editor of Chinese Journal of Medical Image Technology
1994: Third Prize of the Military Science and Technology Progress Award
1997: Second Prize of the Military Science and Technology Progress Award
1997–2009: Standing Member of Chinese Society of Radiology
1999: Third Prize of the Military Science and Technology Progress Award
1999–2010: Deputy Director Member of Chinese Society of Interventional Oncology
2002: Second Prize of the Military Science and Technology Progress Award
2005: Third Prize of the Military Science and Technology Progress Award
Member of Radiological Society of North America(RSNA)
Standing Member of Chinese Society of Radiology
Group Leader of the Group of Intervention of Chinese Journal of Radiology
Deputy Director Member of Chinese Society of Interventional Oncology
Director Member of Beijing Medical Association Society of Interventional Radiology
Deputy Chief Editor of Chinese Journal of Medical Image Technology
Standing Member of Professional Committee of Radiological Medicine of the Chinese People’s Liberation Army
Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology
Awarded the Special Government Allowance of the State Council
Awarded three Second Prizes and four Third Prizes for Military Science and Technology Progress.
Awarded the honorary title of “Chinese College of Interventionalists(CCI) Master Interventionalist”
Led multiple national and provincial/ministerial scientific research projects, including two projects funded by the National Natural Science Foundation of China and two projects funded by the Department of Science and Technology of Sichuan Province.
In the pioneering development of interventional medicine in China, Zhang Jinshan has been an indispensable founder and leading figure. As China’s first overseas-trained doctoral graduate in radiological medicine, he returned to China in the 1980s after completing his studies abroad and introduced cutting-edge international interventional technologies to the country. Over more than four decades of dedicated practice and research, he has helped propel Chinese interventional medicine from its infancy to a position at the forefront of the global field through his exceptional clinical expertise and profound academic accomplishments.
Professor Zhang Jinshan has long been dedicated to the field of medical imaging and has developed distinctive expertise in selective and superselective interventional diagnosis and treatment for solid tumors such as liver cancer, demonstrating exceptional technical proficiency and profound academic accomplishment. Beginning in the 1990s, he led his team in pioneering the clinical application and research of TIPSS and B-ORTO in China, filling major gaps in the domestic field and opening new paths for the interventional management of gastrointestinal bleeding caused by portal hypertension secondary to liver cirrhosis. In addition, he has made groundbreaking contributions to the interventional diagnosis and treatment of peripheral vascular diseases, as well as to preoperative embolization for spinal tumors.
In the field of liver cancer treatment, Professor Zhang Jinshan not only led the development of standardized treatment protocols for liver cancer but also pioneered Transcatheter Arterial Chemoembolization with temporary Hepatic Vein Thrombosis (TACE-THVO) for primary liver cancer, bringing the efficacy of interventional therapy to a new level. In recognition of his outstanding clinical and scientific contributions, he was awarded the honorary title of “Chinese Master of Interventional Radiology” at the 2019 annual conference of the Chinese College of Interventionalists.
Professor Zhang Jinshan is not only a master clinician but also a driving force in the development of the discipline and a dedicated mentor in talent cultivation. He led his team in establishing one of China’s premier interventional therapy centers. As a doctoral supervisor, he has trained a large number of outstanding specialists and future leaders in interventional medicine, with many of his students and protégés now serving across the country. Academically, he has led multiple key national and military research projects, published more than 300 academic papers, and served as chief editor of three monographs, making remarkable contributions to the establishment of China’s academic framework for interventional medicine and the nationwide dissemination of its technologies.
From the laboratory to the operating room, and from academic podiums to grassroots hospitals, Professor Zhang Jinshan has consistently upheld the principles of “pioneering, innovation, pragmatism, and compassion". He has devoted his life to fulfilling the mission of a physician—relieving patients’ suffering through minimally invasive techniques and advancing the discipline through academic excellence—thereby establishing himself as a truly towering figure and one of the foremost authorities in the field of interventional medicine in China.
Professor Zhang Jinshan has achieved prolific academic accomplishments, having published over 300 academic papers covering areas such as interventional therapy for liver cancer, minimally invasive treatment of portal hypertension, interventional treatment of vascular diseases, and tumor ablation.
1. Zhang Jinshan, Wang Maoqiang. Experiments and Clinical Studies of transjugular intrahepatic portosystemic stent shunt (TIPSS). Chinese Journal of Radiology, 1993，27（6）：361-365.
Professor Zhang Jinshan is the first author. This is one of the early research papers in China that systematically elaborates on the TIPSS technique. Through animal experiments and clinical case analysis, it confirmed that TIPSS is a safe and effective minimally invasive method for treating portal hypertension and its complications, laying an important foundation for the promotion and application of this technique in China.
2.Zhang Jinshan, Li Huai. Clinical study on transcatheter arterial embolization with temporary hepatic vein occlusion for the treatment of primary liver cancer.Chinese Journal of Radiology, 1996，30（8）：521-524.
Professor Zhang Jinshan is the first author. He innovatively proposed the technique of "transcatheter arterial embolization with temporary hepatic vein occlusion." Clinical results demonstrated that this method can significantly increase the drug concentration within liver cancer lesions, reduce damage to normal liver tissue, and effectively improve the therapeutic outcomes for intermediate and advanced liver cancer, providing a novel strategy for the interventional treatment of liver cancer.
3. Zhang Jinshan, Wang Maoqiang, Li Huai. Interventional treatment of Budd-Chiari syndrome. Chinese Journal of Medical Imaging Technology, 1998，14（3）：189-191.
Professor Zhang Jinshan is the first author. This paper systematically summarizes the early experience in interventional treatment of Budd-Chiari syndrome in China, elaborating in detail on the key operational points and therapeutic efficacy of techniques such as percutaneous transluminal angioplasty and stent placement. It confirms that interventional therapy is the preferred minimally invasive method for Budd-Chiari syndrome, promoting the standardized development of treatment for this disease.
4.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical value of superselective hepatic arterial chemoembolization in the treatment of hypovascular liver cancer. Chinese Journal of Radiology, 2000，34（5）：335-337.
Professor Zhang Jinshan is the first author. Addressing the challenges in interventional treatment of hypovascular liver cancer, this paper explores the clinical efficacy of superselective hepatic arterial chemoembolization. The results indicate that this technique can precisely target the lesions and improve the treatment response rate, providing an important clinical basis for the interventional treatment of hypovascular liver cancer.
5. Zhang Jinshan, Li Huai, Wang Maoqiang. Interventional treatment of peripheral vascular stenosis and occlusion.Chinese Journal of Radiology, 2002，36（7）：612-614.
Professor Zhang Jinshan is the first author. This paper summarizes the interventional treatment experience of over 400 patients with peripheral vascular stenosis and occlusion, analyzing the indications and efficacy of techniques such as balloon angioplasty and stent placement. It confirms that interventional therapy is a safe and effective approach for peripheral vascular diseases, providing practical support for its clinical promotion.
6.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical application of CT-guided percutaneous puncture ablation in the treatment of abdominal tumors. Chinese Journal of Medical Imaging Technology, 2004，20（9）：1395-1397.
Professor Zhang Jinshan is the first author. This paper explores the application value of CT-guided percutaneous puncture techniques such as radiofrequency ablation and chemical ablation in the treatment of abdominal tumors. The clinical results show that this method is minimally invasive with reliable efficacy, offering a minimally invasive treatment option for patients with inoperable abdominal tumors.
7.Zhang Jinshan, Wang Maoqiang, Li Huai. Advances in the application of interventional therapy for benign prostatic hyperplasia. Chinese Journal of Radiology, 2006，40（8）：876-878.
Professor Zhang Jinshan is the corresponding author. This paper systematically reviews the cutting-edge advances in interventional therapy for benign prostatic hyperplasia, including the principles, procedures, and efficacy of techniques such as prostatic artery embolization and stent placement, providing new insights for the minimally invasive treatment of benign prostatic hyperplasia.
8.Zhang Jinshan, Li Huai, Wang Maoqiang. Discussion on the standardization of interventional therapy for liver cancer. Chinese Journal of Practical Surgery, 2008，28（10）：856-858.
Professor Zhang Jinshan is the corresponding author. Drawing on years of clinical experience and research findings, he led the discussion on standardized protocols for interventional therapy of liver cancer, covering key aspects such as preoperative assessment, treatment modality selection, and postoperative management, providing important references for the formulation of clinical guidelines for interventional therapy of liver cancer in China.
1. Interventional Radiology (People's Military Medical Press, 1995): The first monograph in China to systematically discuss the theories and techniques of interventional radiology. It comprehensively elaborates on the interventional diagnosis and treatment system for tumors, vascular diseases, and non-vascular diseases, becoming a classic essential textbook for interventional physicians in China.
2.Interventional Therapy for Liver Cancer (People's Health Press, 2001): Focusing on minimally invasive interventions for liver cancer, this book systematically summarizes techniques such as TACE, ablation, and vascular intervention, refines operational standards and the prevention and management of complications, and promotes the standardization of interventional therapy for liver cancer.
3.Interventional Treatment of Portal Hypertension (Science Press, 2005): This book systematically elaborates on minimally invasive techniques for portal hypertension, such as TIPSS and B-ORTO, covering experimental research, clinical procedures, long-term follow-up, and efficacy evaluation, filling the gap in monographs on interventional treatment of portal hypertension in China.
1.The National "Eighth Five-Year Plan" Scientific and Technological Key Project—Clinical and Basic Research on Comprehensive Interventional Therapy for Liver Cancer (Project Leader): This project systematically explored multimodal interventional strategies for liver cancer, established the core regimen of superselective TACE combined with local ablation, and significantly improved the therapeutic outcomes for intermediate and advanced liver cancer.
2.The Military "Ninth Five-Year Plan" Key Medical Scientific Research Project—Standardized Research on TIPSS for the Treatment of Portal Hypertension (Project Leader): This project formulated China's first operational standards and postoperative management guidelines for TIPSS, reduced the incidence of complications, and promoted the popularization of this technique throughout the military and across the country.
3.National Natural Science Foundation of China Project — Research on the Mechanism of Targeted Therapy for Liver Cancer Using Hepatic Vein Occlusion Combined with Chemoembolization (Project Leader): This project revealed the synergistic enhancement mechanisms of the innovative technique at the levels of hemodynamics, drug metabolism, and the tumor microenvironment, providing theoretical support for precision interventional therapy of liver cancer.
4.Military Clinical High-Tech Major Project-Establishment and Clinical Application of the Interventional Treatment Technology System for Complex Vascular Diseases (Project Leader): This project overcame interventional challenges in complex lesions such as Budd-Chiari syndrome, peripheral vascular occlusion, and vascular malformations, forming a complete technical system that has been promoted and applied widely.
ラジ・ナガルカール医師は19年間のキャリアの中で50,000件以上の癌手術を行い、HCGマナヴァタ癌センターで患者の生活の質（QOL）の向上に注力しています。
Gül Alço教授は、約27年の経験を持つ放射線腫瘍医です。乳がん、肺がん、前立腺がん、消化器がん、婦人科がん、中枢神経系腫瘍、頭頸部がん、軟部組織腫瘍、骨腫瘍の放射線治療を行っています。
専門分野は、適応放射線治療とラジオサージャリー（放射線外科）です。高度な放射線技術を駆使し、患者中心の多職種連携環境において、個別化された科学的根拠に基づくケアを提供しています。
アブドラ・サキン教授（Prof. Dr. Abdullah Sakin）は、腫瘍内科の教授です。肺がん、乳がん、消化器がん、泌尿器がん、婦人科がん、頭頸部がん、悪性黒色腫（メラノーマ）などの固形腫瘍を専門としています。
科学的根拠に基づいた個別化医療を提供しています。治療法には、化学療法、分子標的療法、免疫療法、ホルモン療法、精密腫瘍学（プレシジョン・オンコロジー）が含まれます。200本以上の科学論文を執筆しており、国際的な臨床研究にも積極的に参加しています。これらの活動は、患者中心のがん医療の発展に寄与しています。
フィリッピーニ教授は、局所進行腫瘍の外科的治療を専門としており、メモリアル・スローン・ケタリングがんセンターおよびシティ・オブ・ホープ腫瘍学センターで研修を受けました。
HCG Manavataがんセンターで放射線治療を専門とするスリダール医師は、数十年にわたる経験と高度な腫瘍学技術への注力を融合させています。
ボルデ医師は、HCG Manavataがんセンターにて30,000件以上のPET検査を担当し、1,000人の甲状腺がん患者を治療してきました。
シュルティ・ケイト医師は、インド有数の癌センターであるタタ記念病院で研修を受け、半骨盤切除術などの複雑な手術を含む外科腫瘍学を専門としています。
アーマー・アリフ・シェイク医師は、口腔顎顔面外科の修士号（MDS）を持ち、頭頸部手術に重点を置いた外科腫瘍学の専門家です。
ラリット・バンスワル博士は、ナシクにあるHCG Manavata Cancer Centreの外科腫瘍医です。10,000件以上の主要な手術を成功させてきました。バンスワル博士は、消化器がんおよびロボット手術技術に重点を置いています。コルカタのタタ・メディカル・センターで2年間のフェローシップを修了しました。
Shaunak Valame医師は、HCG Manavata Cancer Centreにて、標的療法と分子がん研究に重点を置いた半骨盤切除術を専門としています。
| 順位 | 医師 | 経験 | 適合する方 | 特色 | クリニックと所在地 | 診察 |
|---|---|---|---|---|---|---|
| #1 | 20年の経験 | 複雑な癌症例 | フェローシップ訓練をハジェテペ大学がん研究所で修了し、MDアンダーソンでも追加研修を受けた。複数の難治性がん種を専門とする。 | トルコ | から $100 | |
| #2 | 20年の経験 | 複雑な腫瘍症例 | アクデニズ大学での高度なトレーニングを受けた医療腫瘍学の専門家。認定医であり、主要病院での複雑な症例の経験が豊富です。 | トルコ | お問い合わせください | |
| #3 | 30年の経験 | 複雑な癌手術 | 根治的治療と並行して生活の質に焦点を当てています。50,000件以上の癌手術実績。外科腫瘍学の教育および臨床研究における重要人物。 | インド | から $45 | |
| #4 | 46年の経験 | 局所進行腫瘍の切除 | メモリアル・スローン・ケタリングを含む米国のトップがんセンターで研修。低侵襲アプローチを用いた多臓器切除を専門とする。100以上の研究論文を発表。 | イタリア | お問い合わせください | |
| #5 | 30年の経験 | 高度な放射線治療 | 放射線治療の深い専門知識を持つ神経腫瘍学のスペシャリスト。複数の権威ある腫瘍学会の会員であり、最新の治療法の提供を保証します。 | インド | お問い合わせください | |
| #6 | 11年の経験 | 核医学診断 | PETスキャンの豊富な経験を持つ放射性ヨードおよびLu-177療法の専門家。核医学分野の研究者。 | インド | お問い合わせください | |
| #7 | 15年の経験 | 複雑な外科腫瘍学の症例 | 半骨盤切除術などの高度な外科的手技を専門とする。インド有数の癌センターであるタタ記念病院で研修。ASCOおよびESMOの会員。 | インド | お問い合わせください | |
| #8 | 15年の経験 | 口腔がんおよびリハビリテーション | 口腔がん患者の機能的リハビリテーションを専門とし、頭頸部外科腫瘍学のトレーニングを受けている。多数の論文を発表している研究者。 | インド | お問い合わせください | |
| #9 | 10年の経験 | 標的がん療法 | 分子がん研究と標的療法を専門とする。ASCO消化器がんシンポジウムでの発表実績あり。Indraprastha Apollo病院での研修経験。 | インド | お問い合わせください |